1.

正在进行的免疫检查点抑制剂联合放疗的临床研究

Ongoing clinical trials of Immune checkpoint inhibitors combined with radiotherapy

Clinical trials /NCT number	Phase	PD-1/PD-L1 agent	Condition or disease	Study design	Predict time of completion
ICI: immune checkpoint inhibitor; NSCLC: non-small cell lung cancer; PD-1: programmed death-1.
RTOG 3505/NCT02768558	Phase Ⅲ	Nivolumab	Stage Ⅲ, unresectable NSCLC	4 wk-12 wk ICI as maintenance after concurrent chemoradiotherapy	January 2019
NICOLAS/NCT02434081	Phase Ⅱ	Nivolumab	Stage Ⅲa/Ⅲb, locally advanced NSCLC	Concurrent ICI to standard first-line chemotherapy and radiotherapy	August 2020
DETERRED/NCT02525757	Phase Ⅱ	Atezolizumab	Locally advanced NSCLC	Concurrent ICI to standard first-line chemotherapy and radiotherapy	January 2020
NCT 03102242	Phase Ⅱ	Atezolizumab	Stage Ⅲ, unresectable NSCLC	ICI as induction/consolidation therapy (single arm)	March 2020
NRG LU004 ARCHON-1/NCT03801902	Phase Ⅰ	Durvalumab	PD-L1 overexpression, stage Ⅱ-Ⅲ, recurrent NSCLC	ICI combined with radiotherapy	July 28, 2020